Antiretroviral Therapy and Weight Gain
Modern HIV treatment commonly leads to weight gain, particularly combinations built on integrase inhibitors and tenofovir alafenamide - and the gain can be managed without stopping treatment.
Plain English
Patient-Friendly Explanation
Antiretroviral therapy is the combination of medicines that keeps HIV under control and gives people with HIV a normal life expectancy. A recognised side effect of the newer regimens is weight gain. Some of this is welcome and expected: when HIV is untreated it wastes the body, so recovering weight in the first months of treatment is a return to health. But many people continue gaining after that point, particularly with regimens containing an integrase inhibitor such as dolutegravir or bictegravir, and with tenofovir alafenamide replacing the older tenofovir disoproxil. Average gains of a few kilograms over the first year or two are common, and the effect is larger in women and in people of African ancestry. Gaining weight matters because it increases the risk of diabetes, fatty liver and heart disease on top of any HIV-related risk. The important message is that treatment must never be stopped or changed on your own - your HIV doctor can review alternatives - and that the weight itself responds to the same measures as any other weight problem: diet quality, activity, and where appropriate medically supervised treatment.
Medical
Clinical Definition
Weight gain on antiretroviral therapy is now well characterised. Randomised and observational data show that integrase strand transfer inhibitor-based regimens, particularly dolutegravir and bictegravir, and tenofovir alafenamide in place of tenofovir disoproxil fumarate, are associated with greater weight gain than efavirenz-based or TDF-containing comparators, with mean increases of roughly 2 to 5 kg over one to two years and larger increases in some subgroups. This is not merely a return-to-health effect: in treatment-naive trials, separating the early catch-up phase leaves a genuine drug-attributable gain, and the effect is most marked in women, in people of Black African ancestry, and in those with lower baseline CD4 counts or higher baseline BMI. The mechanism is not settled; proposed contributors include off-target effects on adipocyte differentiation and lipogenesis, altered central appetite signalling, changes in the gut microbiome, and reduced energy expenditure, and TDF's weight-suppressing effect may partly explain the difference when it is replaced. Weight and central adiposity increase the risk of incident diabetes, dyslipidaemia, hypertension and MASLD in people living with HIV, a population already at elevated cardiovascular risk. Management is multifactorial: structured diet and exercise intervention, aggressive control of lipids, blood pressure and glycaemia, consideration of regimen switches (for example back to TDF or efavirenz where clinically acceptable) and, in selected patients, weight-management pharmacotherapy under specialist supervision. Antiretroviral therapy itself must not be interrupted or altered outside infectious disease review.
Key Insight
Why It Matters
Weight gain on HIV treatment is a recognised drug effect, not a failure on your part - but it is still worth taking seriously, because it adds to heart and diabetes risk. Never change your HIV medicines yourself; we work alongside your HIV doctor and build a weight plan around the regimen you need to stay on.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
